+ Watch NPSP
on My Watchlist
A biopharmaceutical company focused on the development and commercialization of small molecule drugs and recombinant proteins.
The spike will decay from the announcement that the U.S. Food and Drug Administration (FDA) has approved Gattex (Teduglutide [rDNA origin]) for Injection, for subcutaneous use for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Gattex will be available in the first quarter of 2013. In the near term the share price will suffer until the market proves the revenue potential of the drug.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions